210 related articles for article (PubMed ID: 31787505)
21. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
22. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
[TBL] [Abstract][Full Text] [Related]
23. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.
Gao J; Qiu X; Li X; Fan H; Zhang F; Lv T; Song Y
Biochem Biophys Res Commun; 2018 Apr; 498(3):409-415. PubMed ID: 29452091
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
25. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
26. In vitro evaluation of Neosetophomone B inducing apoptosis in cutaneous T cell lymphoma by targeting the FOXM1 signaling pathway.
Kuttikrishnan S; Masoodi T; Ahmad F; Sher G; Prabhu KS; Mateo JM; Buddenkotte J; El-Elimat T; Oberlies NH; Pearce CJ; Bhat AA; Alali FQ; Steinhoff M; Uddin S
J Dermatol Sci; 2023 Nov; 112(2):83-91. PubMed ID: 37865581
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
28. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
29. Intestinal Lamina Propria CD4
Yu X; Zhang H; Yu L; Liu M; Zuo Z; Han Q; Zhang J; Tian Z; Zhang C
Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29844236
[TBL] [Abstract][Full Text] [Related]
30. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
[TBL] [Abstract][Full Text] [Related]
31. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma.
Chen Z; Dong D; Zhu Y; Pang N; Ding J
FASEB J; 2021 Mar; 35(3):e21401. PubMed ID: 33559190
[TBL] [Abstract][Full Text] [Related]
32. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
33. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma.
Wollina U; Graefe T; Feldrappe S; André S; Wasano K; Kaltner H; Zick Y; Gabius HJ
J Cancer Res Clin Oncol; 2002 Feb; 128(2):103-10. PubMed ID: 11862481
[TBL] [Abstract][Full Text] [Related]
34. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Braun FK; Fecker LF; Schwarz C; Walden P; Assaf C; Dürkop H; Sterry W; Eberle J
J Invest Dermatol; 2007 Oct; 127(10):2425-37. PubMed ID: 17495957
[TBL] [Abstract][Full Text] [Related]
35. Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155.
Takahashi N; Sugaya M; Suga H; Oka T; Kawaguchi M; Miyagaki T; Fujita H; Inozume T; Sato S
J Invest Dermatol; 2017 Aug; 137(8):1766-1773. PubMed ID: 28395975
[TBL] [Abstract][Full Text] [Related]
36. Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4
Zhuo Y; Zhang YF; Wu HJ; Qin L; Wang YP; Liu AM; Wang XH
Biomed Pharmacother; 2017 Oct; 94():386-393. PubMed ID: 28772217
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
38. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
[TBL] [Abstract][Full Text] [Related]
39. Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.
Liu Y; Ji H; Zhang Y; Shen X; Gao F; He X; Li GA; Busuttil RW; Kuchroo VK; Kupiec-Weglinski JW
J Hepatol; 2015 Mar; 62(3):563-72. PubMed ID: 25450716
[TBL] [Abstract][Full Text] [Related]
40. Oridonin Could Inhibit Inflammation and T-cell Immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) Autocrine Loop in the Acute Myeloid Leukemia Cell Line (U937) as Compared to Doxorubicin.
Nasri F; Sadeghi F; Behranvand N; Samei A; Bolouri MR; Azari T; Abdollahi E; Ghazizadeh F; Motevalian M; Hassan ZM; Falak R
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):602-611. PubMed ID: 33463129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
